Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib Versus Upadacitinib as Add-on to Methotrexate in Rheumatoid Arthritis
NCT07636057Phase 4Not yet recruiting
- Sponsor
- Sheikh Zayed Federal Postgraduate Medical Institute
- Start
- Jul 2026
- Primary completion
- Mar 2027
01
Overview
A Phase 4 trial of tofacitinib oral solution, upadacitinib in rheumatoid arthritis (RA), sponsored by Sheikh Zayed Federal Postgraduate Medical Institute. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
tofacitinib oral solutionupadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT07636057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07636057.